Fig. 4From: Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE studyProbability of meaningful within-patient change†in VAS score (Weeks 49–52). *P < 0.001; † ≥ 2.5-point change (improvement) for overall symptoms, nasal discharge, and facial pain VAS scores, and a ≥ 3-point change (improvement) for nasal obstruction, loss of sense of smell, and mucus in throat VAS scores. CI Confidence interval, VAS Visual analogue scaleBack to article page